Glycotest Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$3.22M
- Investors
-
5
Glycotest General Information
Description
Developer of a liver disease diagnostics technology intended to commercialize new and unique blood tests for life-threatening cancers and fibrosis-cirrhosis. The company's platform provides non-invasive blood tests based on proprietary serum biomarkers, biomarker panels, and assay technology that exploit novel sugar-based disease signal chemistry, enabling patients with serious diseases to access novel clinical laboratory testing services and experience early detection of liver cancer and chronic disease.
Contact Information
Website
www.glycotest.comCorporate Office
- 613 Schiller Avenue
- Suite 817
- Merion, PA 19066
- United States
Corporate Office
- 613 Schiller Avenue
- Suite 817
- Merion, PA 19066
- United States
Glycotest Timeline
Glycotest Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 16-Jul-2026 | $3.22M | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 6. Later Stage VC (Series A) | 23-Jan-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jun-2019 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series A) | 05-Feb-2019 | Completed | Clinical Trials - Phase 3 | |||
| 3. Buyout/LBO | 31-Dec-2016 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 05-Jun-2012 | $500K | $500K | Completed | Stealth | |
| 1. University Spin-Out | 01-Jan-2012 | Completed | Stealth |
Glycotest Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-4 | 5,846,587 | $0.001000 | 8% | $0.38 | $0.38 | 1x | $0.38 | 3.48% |
| Series A-1 | 40,785,357 | $0.001000 | 8% | $0.51 | $0.51 | 1x | $0.51 | 24.29% |
Glycotest Comparisons
Industry
Financing
Details
Glycotest Competitors (1)
One of Glycotest’s competitors is Wako., a Corporation company based in Enid, OK.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Wako. | Corporation | Enid, OK |
Glycotest Signals
Glycotest Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MedTech Innovator | Accelerator/Incubator | Minority | ||
| Baruch S. Blumberg Institute | Corporation | Minority | ||
| Fosun Pharma | Corporation | Majority | ||
| EMV Capital | Venture Capital | Minority | ||
| Drexel University | University | Minority |
Glycotest FAQs
-
When was Glycotest founded?
Glycotest was founded in 2012.
-
Where is Glycotest headquartered?
Glycotest is headquartered in Merion, PA.
-
What is the size of Glycotest?
Glycotest has 2 total employees.
-
What industry is Glycotest in?
Glycotest’s primary industry is Biotechnology.
-
Is Glycotest a private or public company?
Glycotest is a Private company.
-
What is the current valuation of Glycotest?
The current valuation of Glycotest is .
-
What is Glycotest’s current revenue?
The current revenue for Glycotest is .
-
How much funding has Glycotest raised over time?
Glycotest has raised $16.2M.
-
Who are Glycotest’s investors?
MedTech Innovator, Baruch S. Blumberg Institute, Fosun Pharma, EMV Capital, and Drexel University have invested in Glycotest.
-
Who are Glycotest’s competitors?
Wako. is a competitor of Glycotest.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process